Veritas In Silico (130A) · TargetReframedLatest Share Issuance and Disposal (2026-10-13): "Restated"
Transformation into a Specialty Pharma Company
First written in FY2023. 1 of 3 entries say "Reframed", first in FY2025. Latest entry: 2026-10-13.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
Corporate Transformation into a Global Mid-Sized Pharmaceutical CompanyA theme 9 companies write about · 0 as a headwind · 9 as a tailwind
The whole theme swung hardest in 2025: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-10-13RestatedShare Issuance and Disposal
「2030年のスペシャリティファーマ確立に向け、プラットフォーム型ビジネスを基盤に共同創薬研究から自社パイプラインを組み合わせたハイブリッド型へと段階的にビジネスモデルを進化させ、複数の収益源を確立して企業価値の向上を目指す。」
2030年のスペシャリティファーマ確立と、プラットフォーム型・パイプライン型を組み合わせるハイブリッド型への移行方針を再掲している。 - FY2025ReframedAnnual report
「As a medium- to long-term objective, we aim to establish a firm position as a specialty pharma by around 2030.」
The previous long-term vision of changing business format has been clarified as a target for around 2030 and described as a phased transition from a platform business to a hybrid business and then to a pharmaceutical company with the necessary capabilities. - FY2023First statedAnnual report
「Over the longer term, we aim to achieve sustainable business growth by transitioning from a biotech company specializing in drug-discovery research to a pharmaceutical company, or specialty pharma, equipped with research and development, sales and other functions.」
The company has set out a long-term vision of becoming a pharmaceutical company with research, development and sales functions.